The announcement of these non-binding term sheets with an undisclosed biotech company represents a significant potential revenue source for Enveric Biosciences. The potential for up to $82 million in milestone payments, along with royalties on future sales, is a strong positive signal to investors about the value of Enveric's asset portfolio and its future revenue prospects. This news directly impacts ENVB's stock, as evidenced by the 66.10% increase in its price, indicating investor optimism about the deal's future financial benefits.